August 25, 2016 09:06 AM EDTUpdated September 18, 06:22 PM
Startups
R&D
News Briefing

Pro­to­cols: BeiGene signs up Medi­va­tion’s Amy Pe­ter­son as its new CMO; Ac­ne drug de­vel­op­er files for $60M IPO

John Carroll

Editor & Founder

Now that Pfiz­er has bagged Medi­va­tion in its $14 bil­lion buy­out deal, the scram­ble for top tal­ent has be­gun. Chi­na’s BeiGene was one of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times